Sign In
Buy AQST
$4.03
+0.100 (+2.54%)
At Close: Jun 03, 2026
Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?
10:50am, Friday, 26'th May 2023
Here is how Aquestive Therapeutics (AQST) and Corvus Pharmaceuticals (CRVS) have performed compared to their sector so far this year.
Are You Looking for a Top Momentum Pick? Why Aquestive Therapeutics (AQST) is a Great Choice
01:44pm, Thursday, 11'th May 2023
Does Aquestive Therapeutics (AQST) have what it takes to be a top stock pick for momentum investors? Let's find out.
Best Momentum Stocks to Buy for May 9th
11:27am, Tuesday, 09'th May 2023
AQST, PLTK and WWD made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 9, 2023.
Aquestive Therapeutics (AQST) Tops Q1 Earnings and Revenue Estimates
07:54pm, Tuesday, 02'nd May 2023
Aquestive Therapeutics (AQST) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of a loss of $0.10 per share. This compares to loss of $0.32 per share a year ag
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
08:00am, Wednesday, 26'th Apr 2023
WARREN, N.J., April 26, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care an
Aquestive Therapeutics, Inc. (AQST) Q4 2022 Earnings Call Transcript
11:45am, Wednesday, 08'th Mar 2023
Aquestive Therapeutics, Inc. (NASDAQ:AQST ) Q4 2022 Results Conference Call March 8, 2023 8:00 AM ET Company Participants Bennett Watson - Westwicke, Investor Relations Dan Barber - Chief Executive Of
Aquestive Therapeutics (AQST) Reports Q4 Loss, Tops Revenue Estimates
06:48pm, Tuesday, 07'th Mar 2023
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -9.52% and 7.57%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stoc
WARREN, N.J., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients' pro
Aquestive Therapeutics: Going All-In On AQST-109
03:18am, Tuesday, 29'th Nov 2022
Aquestive Therapeutics has been making deals to generate cash to help develop their epinephrine candidate, AQST-109. Aquestive appears to be going all-in on AQST-109's clinical and commercial success.
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
08:00am, Tuesday, 15'th Nov 2022
WARREN, N.J., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (Nasdaq: AQST), a pharmaceutical company advancing current standards of care to solve patients' problems through simplifyin
WARREN, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing current standards of care to solve patients' problems through simplifyin
My Top 5 U.S. Stocks Under $10
06:00am, Thursday, 03'rd Nov 2022
After a rough September, we're approaching the season historically known for stronger performance. Although small-cap stocks can be more volatile than large-caps, cheap stocks often have high return p
Aquestive Therapeutics, Inc. (AQST) Q3 2022 Earnings Call Transcript
09:44am, Wednesday, 02'nd Nov 2022
Aquestive Therapeutics, Inc. (NASDAQ:AQST ) Q3 2022 Earnings Conference Call November 2, 2022 8:00 AM ET Company Participants Bennett Watson - Westwicke, Investor Relations Dan Barber - Chief Executiv
Aquestive Therapeutics (AQST) Reports Q3 Loss, Tops Revenue Estimates
06:50pm, Tuesday, 01'st Nov 2022
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 23.33% and 7.30%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the sto
WARREN, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing current standards of care to solve patients' problems through simplifyin
